Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Fate Therapeutics' Leadership Changes

This article was originally published in Scrip

Executive Summary

Fate Therapeutics has appointed Scott Wolchko president and CEO following Christian Weyer's resignation – effective Nov. 30, 2015. Wolchko, who was chief financial officer (CFO) since the company was found in 2007 and chief operating officer since January 2013, has also joined Fate's board of directors. Prior to Fate, Wolchko was CFO of an enterprise software company, Bocada Inc. In addition to Wolchko's appointment, Dr. Daniel Shoemaker has been promoted to chief scientific officer from chief technology officer; Dr. Stewart Abbot, formerly vice-president of translational research, has been named chief development officer; and Cindy Tahl has been promoted to general counsel after being the company's senior legal counsel since 2009.






Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst